TAK1/MAP4K2 inhibitor 1 | MAP4K Inhibitor | AmBeed-信号通路专用抑制剂

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

产品名称	A-raf ↓ ↑	B-Raf ↓ ↑	C-Raf/Raf-1 ↓ ↑	Raf ↓ ↑	其他靶点	纯度
Encorafenib		✔				99%+
GDC-0879		++++ B-Raf, IC50: 0.13 nM				99%+
SB-590885		++++ B-Raf, Ki: 0.16 nM				99%+
RAF265						99%+
Dabrafenib		++++ B-Raf, IC50: 5.2 nM B-Raf (V600E), IC50: 0.7 nM	+++ C-Raf, IC50: 6.3 nM			98%
Lifirafenib	++++ WT A-RAF, IC50: 1 nM	++ BRAF WT, IC50: 32 nM BRAF(V600E), IC50: 23 nM	+++ C-RAF (Y340/341D), IC50: 7 nM		EGFR	98%
ZM 336372			+ C-Raf, IC50: 70 nM			99%+
NVP-BHG 712			+ C-Raf, IC50: 0.395 μM			99%+
CCT196969		+ BRAF, IC50: 0.1 μM	++ CRAF, IC50: 0.01 μM		Src	98%
Vemurafenib		++ B-Raf, IC50: 100 nM B-Raf (V600E), IC50: 31 nM	+ C-Raf, IC50: 48 nM			98+%
PLX4720		++ B-Raf, IC50: 160 nM B-Raf (V600E), IC50: 13 nM	+++ C-Raf-1 (Y340D/Y341D), IC50: 6.7 nM		BRK	99+%
GW 5074			+++ C-Raf, IC50: 9 nM			99%+
Avutometinib		+++ BRAF, IC50: 19 nM BRAF V600E, IC50: 8.2 nM	+ CRAF, IC50: 56 nM			98%
LY3009120		++++ BRAF WT, IC50: 15 nM BRAF(V600E), IC50: 5.8 nM	++++ C-Raf, IC50: 4.3 nM			99%+
Agerafenib		++ B-Raf (V600E), Kd: 14 nM B-Raf, Kd: 36 nM	+ C-Raf, Kd: 39 nM		RET	99%+
TAK-632		+++ B-Raf, IC50: 8.3 nM	++++ C-Raf, IC50: 1.4 nM			99%+
AZ 628		+ B-Raf, IC50: 105 nM B-Raf (V600E), IC50: 34 nM	++ C-Raf-1, IC50: 29 nM			99%
PLX7904				✔		98+%
Sorafenib		++ B-Raf, IC50: 22 nM B-Raf (V599E), IC50: 38 nM	++++ Raf-1, IC50: 6 nM	++++ Raf-1, IC50: 6 nM		99%
Tovorafenib				✔		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT03181100	Malignant Neoplasms of Thyroid... 展开 >> and Other Endocrine Glands Anaplastic Thyroid Carcinoma Poorly Differentiated Thyroid Cancer 收起 <<	Phase 2	Recruiting	July 2023	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Clinical Research Operations mcabani@mdanderson.org Contact mcabani@mdanderson.org 收起 <<
NCT01978236	Melanoma and Brain Metastases	Phase 2	Terminated(This study was term... 展开 >>inated due to the limited enrollment.) 收起 <<	-	United States, Pennsylvania ... 展开 >> GSK Investigational Site Pittsburgh, Pennsylvania, United States, 15232 United States, Texas GSK Investigational Site Houston, Texas, United States, 77030 Australia, New South Wales GSK Investigational Site North Sydney, New South Wales, Australia, 2060 收起 <<
NCT01738451	Cancer	Phase 1	Completed	-	United States, Arizona ... 展开 >> GSK Investigational Site Scottsdale, Arizona, United States, 85259 United States, Tennessee GSK Investigational Site Memphis, Tennessee, United States, 38120 GSK Investigational Site Nashville, Tennessee, United States, 37203 United States, Texas GSK Investigational Site San Antonio, Texas, United States, 78229 United States, Utah GSK Investigational Site Salt Lake City, Utah, United States, 84112-5550 Australia, Victoria GSK Investigational Site Heidelberg, Victoria, Australia, 3084 GSK Investigational Site Melbourne, Victoria, Australia, 3004 United Kingdom GSK Investigational Site London, United Kingdom, W1G 6AD 收起 <<
NCT01978236	-		Terminated(This study was term... 展开 >>inated due to the limited enrollment.) 收起 <<	-	-
NCT01682083	Melanoma	Phase 3	Active, not recruiting	November 30, 2030	-
NCT01682083	-		Active, not recruiting	-	-
NCT03176485	Metastatic Cancer ... 展开 >> Melanoma Colon Cancer Differentiated Thyroid Cancer Hepatocellular Carcinoma Renal Cell Carcinoma Metastatic Melanoma HCC Metastatic Colon Cancer 收起 <<	Not Applicable	Recruiting	November 1, 2018	United States, Arizona ... 展开 >> University of Arizona Cancer Center Recruiting Tucson, Arizona, United States, 85724 Contact: Clara Curiel-Lewandroski ccuriel@email.arizona.edu 收起 <<
NCT01909453	Melanoma	Phase 3	Active, not recruiting	March 31, 2019	-
NCT01231568	Cancer	Phase 1	Completed	-	United States, Arizona ... 展开 >> GSK Investigational Site Scottsdale, Arizona, United States, 85259 United States, Michigan GSK Investigational Site Detroit, Michigan, United States, 48201 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37203 United States, Utah GSK Investigational Site Salt Lake City, Utah, United States, 84112 收起 <<
NCT01266967	Melanoma and Brain Metastases	Phase 2	Completed	-	-
NCT01266967	-		Completed	-	-
NCT01689519	Malignant Melanoma	Phase 3	Active, not recruiting	December 28, 2019	-
NCT02425904	Langerhans Cell Histiocytosis	Phase 2	Recruiting	September 2022	United States, Arizona ... 展开 >> Phoenix Children's Hospital Recruiting Phoenix, Arizona, United States, 85016 Contact: Michael Henry, MD 602-933-0920 MHenry@phoenixchildrens.com United States, Arkansas Arkansas Children's Hospital Recruiting Little Rock, Arkansas, United States, 72202 Contact: Kimo Stine, MD 501-364-1494 StineKimoC@uams.edu United States, California Children's Hospital of Los Angeles Recruiting Los Angeles, California, United States, 90027 Contact: Rima Jubran, MD 323-361-5639 rjubran@chla.usc.edu University of California San Francisco Medical Center Recruiting San Francisco, California, United States, 94143 Contact: Michelle Hermiston, MD 415-476-3831 HermistonM@peds.ucsf.edu United States, District of Columbia Children's National Medical Center Recruiting Washington, District of Columbia, United States, 20010 Contact: Stephen Ladisch, MD sladisch@childrensnational.org United States, Massachusetts Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: David Ebb, MD 617-726-2737 DEBB@mgh.harvard.edu Boston Children's Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Barbara Degar, MD 617-632-5186 Barbara_Degar@dfci.harvard.edu Principal Investigator: Barbara Degar, MD Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02115 Contact: Barbara Degar, MD 617-632-5186 barbara_degar@dfci.harvard.edu Principal Investigator: Barbara Degar, MD Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Eric Jacobsen, MD 617-632-6633 EdJacobsen@partners.org United States, New York Mount Sinai Medical Center Recruiting New York, New York, United States, 10029 Contact: Birte Wistinghausen, MD 212-241-7022 Birte.wistinghausen@mssm.edu United States, Ohio Cincinnati Children's Hospital Medical Center Recruiting Cincinnati, Ohio, United States, 45229 Contact: Ashish Kumar, MD 513-803-1631 Ashish.Kumar@cchmc.org United States, Pennsylvania The Children's Hospital of Pennsylvania Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Michael Hogarty, MD 215-590-2821 hogartym@email.chop.edu United States, Tennessee St. Jude Children's Research Hospital Recruiting Memphis, Tennessee, United States, 38105 Contact: Patrick Campbell, MD patrick.campbell@stjude.org Principal Investigator: Patrick Campbell, MD United States, Texas Texas Children's Hospital Recruiting Houston, Texas, United States, 77030 Contact: Carl Allen, MD 832-822-4890 ceallen@txch.org 收起 <<
NCT01940809	BRAF V600E Mutation Present ... 展开 >> BRAF V600K Mutation Present Metastatic Melanoma Stage III Cutaneous Melanoma AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 收起 <<	Phase 1	Active, not recruiting	-	United States, Massachusetts ... 展开 >> Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 收起 <<
NCT01689519	-		Active, not recruiting	-	-
NCT03430947	Malignant Melanoma Stage IV ... 展开 >> BRAF V600 Mutation Brain Metastases 收起 <<	Phase 2	Recruiting	August 31, 2021	Germany ... 展开 >> Technische Universität Dresden Recruiting Dresden, Germany, 01307 Contact: Friedegund Meier, MD +49 351 458 ext 2497 friedegund.meier@uniklinikum-dresden.de Contact: Esther Troost, MD +49 351 458 ext 2394 esther.troost@uniklinikum-dresden.de Principal Investigator: Friedegund Meier, MD Principal Investigator: Esther Troost, MD, PhD Ruprecht-Karls-University of Heidelberg, Faculty of Medicine Not yet recruiting Heidelberg, Germany, 69120 Contact: Jessica Hassel, MD Eberhard Karls University of Tübingen, University Medical Center Not yet recruiting Tuebingen, Germany, 72076 Contact: Thomas Eigentler, MD 收起 <<
NCT01262963	Cancer	Phase 1	Completed	-	United States, Washington ... 展开 >> GSK Investigational Site Tacoma, Washington, United States, 98418 收起 <<
NCT03088176	Melanoma BRAF... 展开 >> Gene Mutation 收起 <<	Phase 1	Recruiting	June 30, 2021	United States, Tennessee ... 展开 >> West Cancer Center Recruiting Germantown, Tennessee, United States, 38138 Contact: Ari VanderWalde, MD, MPH 901-683-0055 ext 63015 avanderw@westclinic.com Contact: Nibedita Chakraborty 901-683-0055 ext 63023 nchakraborty@westclinic.com 收起 <<
NCT03101254	Melanoma	Phase 1 Phase 2	Recruiting	October 30, 2023	United States, Massachusetts ... 展开 >> Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Elizabeth Buchcinder, MD 617-632-5055 Principal Investigator: Elizabeth Buchbinder, MD 收起 <<
NCT03618641	Melanoma Lymp... 展开 >>h Node Cancer 收起 <<	Phase 2	Recruiting	July 15, 2023	United States, Pennsylvania ... 展开 >> UPMC Hillman Cancer Center Recruiting Pittsburgh, Pennsylvania, United States, 15232 Contact: Diwakar Davar, MD 412-623-7368 davard@upmc.edu Contact: Amy Rose, RN 412-647-8587 kennaj@upmc.edu 收起 <<
NCT02837263	Colorectal Cancer ... 展开 >> Colorectal Adenocarcinoma Stage IVA Colorectal Cancer Stage IVB Colorectal Cancer Metastatic Carcinoma in the Liver 收起 <<	Phase 1	Recruiting	June 2021	United States, Wisconsin ... 展开 >> University of Wisconsin Carbone Cancer Center Recruiting Madison, Wisconsin, United States, 53792 Contact: Cancer Connect 800-622-8922 cancerconnect@uwcarbone.wisc.edu Principal Investigator: Dustin Deming 收起 <<
NCT01840527	-		Active, not recruiting	March 2019	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 收起 <<
NCT01585415	Metastatic Cancer ... 展开 >> Melanoma 收起 <<	Phase 1	Terminated	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT02367859	Ameloblastoma ... 展开 >> BRAF Gene Mutation 收起 <<	Phase 2	Recruiting	August 2020	United States, California ... 展开 >> Stanford University, School of Medicine Recruiting Stanford, California, United States, 94305 Contact: Elizabeth Winters 650-721-6509 ewinters@stanford.edu Principal Investigator: Alexander D. Colevas Sub-Investigator: Jonathan Pollack Sub-Investigator: Davud Sirjani Sub-Investigator: Robert West 收起 <<
NCT02910700	BRAF Gene Mutation ... 展开 >> BRAF wt Allele Stage III Cutaneous Melanoma AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 收起 <<	Phase 2	Recruiting	December 31, 2021	United States, Texas ... 展开 >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Hussein A. Tawbi 713-792-2921 Principal Investigator: Hussein A. Tawbi 收起 <<
NCT01231594	Cancer	Phase 1	Completed	-	-
NCT02097225	BRAF V600E Mutation Present ... 展开 >> BRAF V600K Mutation Present Metastatic Malignant Solid Neoplasm Metastatic Melanoma Stage III Cutaneous Melanoma AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 Unresectable Solid Neoplasm 收起 <<	Phase 1	Recruiting	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Cancer Center Recruiting Boston, Massachusetts, United States, 02114 Contact: Ryan J. Sullivan 617-724-4000 rsullivan7@partners.org Principal Investigator: Ryan J. Sullivan Dana-Farber Cancer Institute Suspended Boston, Massachusetts, United States, 02215 收起 <<
NCT01989585	BRAF V600E Mutation Present ... 展开 >> BRAF V600K Mutation Present Metastatic Melanoma Solid Neoplasm Stage III Cutaneous Melanoma AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 收起 <<	Phase 1 Phase 2	Recruiting	-	United States, California ... 展开 >> University of California Davis Comprehensive Cancer Center Suspended Sacramento, California, United States, 95817 United States, Massachusetts Massachusetts General Hospital Cancer Center Withdrawn Boston, Massachusetts, United States, 02114 United States, Missouri Siteman Cancer Center at West County Hospital Suspended Creve Coeur, Missouri, United States, 63141 Washington University School of Medicine Suspended Saint Louis, Missouri, United States, 63110 Siteman Cancer Center-South County Suspended Saint Louis, Missouri, United States, 63129 Siteman Cancer Center at Christian Hospital Suspended Saint Louis, Missouri, United States, 63136 Siteman Cancer Center at Saint Peters Hospital Suspended Saint Peters, Missouri, United States, 63376 United States, New Jersey Rutgers Cancer Institute of New Jersey Recruiting New Brunswick, New Jersey, United States, 08903 Contact: Site Public Contact 732-235-8675 Principal Investigator: Janice M. Mehnert United States, North Carolina Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: Site Public Contact 888-275-3853 Principal Investigator: James L. Abbruzzese United States, Ohio Ohio State University Comprehensive Cancer Center Recruiting Columbus, Ohio, United States, 43210 Contact: Site Public Contact 800-293-5066 Jamesline@osumc.edu Principal Investigator: Kari L. Kendra United States, Texas M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Site Public Contact 877-312-3961 Principal Investigator: Michael A. Davies 收起 <<
NCT03493932	Glioblastoma	Phase 1	Recruiting	June 1, 2021	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 prpl@cc.nih.gov 收起 <<
NCT02475213	Melanoma Head... 展开 >> and Neck Cancer Non Small Cell Lung Cancer Urethelial Carcinoma 收起 <<	Phase 1	Recruiting	August 2020	United States, Arizona ... 展开 >> Mayo Clinic - AZ Not yet recruiting Scottsdale, Arizona, United States, 85259 Principal Investigator: Ramesh Ramanathan, MD United States, Florida Boca Raton Regional Hospital Not yet recruiting Boca Raton, Florida, United States, 33486 Principal Investigator: Edgardo Santos Castillero, MD Mayo Clinic - FL Not yet recruiting Jacksonville, Florida, United States, 32224 Principal Investigator: Yanyan Lou, MD, PhD Moffitt Cancer Center Recruiting Tampa, Florida, United States, 33612 Contact: Kristina Trajic 813-745-4673 ext 1480 Kristina.trajic@moffitt.org Principal Investigator: Scott Antonia, MD United States, Kentucky Norton Cancer Institute Research Program Active, not recruiting Louisville, Kentucky, United States, 40202 United States, Maryland University of Maryland Greenbaum Cancer Center Recruiting Baltimore, Maryland, United States, 21201 Contact: Cheryl Young Cheryl.Young@umm.edu Principal Investigator: Dan Zandberg, MD United States, Massachusetts Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Tess Ferguson 617-632-1991 tessk_ferguson@dfci.harvard.edu Principal Investigator: Osama Rahma, MD United States, Michigan South Texas Accelerated Research Therapeutics, LLC - Midwest Recruiting Grand Rapids, Michigan, United States, 49503 Contact: Kathy Estkowski 616-954-5551 kathy.estkowski@startmidwest.com Principal Investigator: Nehal Lakhani, MD, PhD United States, Minnesota Mayo Clinic - MN Not yet recruiting Rochester, Minnesota, United States, 55905 Principal Investigator: Alex Adjei, MD, PhD United States, Nebraska Nebraska Cancer Specialists Recruiting Omaha, Nebraska, United States, 68130 Contact: Gladys Pierce 402-690-6972 gpierce@nebraskacancer.com Principal Investigator: Ralph Hauke, MD United States, Nevada Comprehensive Cancer Centers of Nevada Recruiting Las Vegas, Nevada, United States, 89169 Contact: Kim Bradstreet, RN 702-952-3443 kimberly.bradstreet@usoncology.com Principal Investigator: Nicholas Vogelzang, MD United States, New York Roswell Park Cancer Institute Not yet recruiting Buffalo, New York, United States, 14263 Contact: Dawn DePaolo DawnMarie.DePaolo@RoswellPark.org Principal Investigator: Gurkamal Chatta, MD Columbia University Medical Center Recruiting New York, New York, United States, 10032 Contact: Molly McGuinness 212-304-5552 mm5016@cumc.columbia.edu Principal Investigator: Naiyer Rizvi, MD United States, Ohio Gabrail Cancer Institute Not yet recruiting Canton, Ohio, United States, 44718 Principal Investigator: Nashat Gabrail, MD United States, Pennsylvania Hospital of the University of Pennsylvania/Abramson Cancer Center Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Maryann Ghallagher, RN 215-662-7758 maryann.gallagher@uphs.upenn.edu Principal Investigator: Charu Aggarwal, MD University of Pittsburg Recruiting Pittsburgh, Pennsylvania, United States, 15232 Contact: Shea McQuilkin, BSN, RN 412-623-6650 mcquilkinm@upmc.edu Principal Investigator: Robert Ferris, MD United States, Rhode Island Rhode Island Hospital Not yet recruiting Providence, Rhode Island, United States, 02903 Principal Investigator: Ariel Birnbaum, MD United States, South Carolina Greenville Health System Not yet recruiting Greenville, South Carolina, United States, 29605 Contact: Lisa Johnson 864-455-3735 ljohnson4@ghs.org Principal Investigator: Jeffery Edenfield, MD United States, Texas Mary Crowley Cancer Research Center Not yet recruiting Dallas, Texas, United States, 75230 Principal Investigator: James Strauss, MD South Texas Accelerated Research Therapeutics, LLC Recruiting San Antonio, Texas, United States, 78229 Contact: Christina Duralde, RN, MSN 210-593-5242 christina.duralde@start.stoch.com Principal Investigator: Anthony Tolcher, M.D. 收起 <<
NCT01902173	Adult Solid Neoplasm ... 展开 >> Recurrent Colon Carcinoma Recurrent Melanoma Recurrent Ovarian Carcinoma Stage IIIC Colon Cancer Stage IIIC Ovarian Cancer Stage IIIC Skin Melanoma Stage IV Skin Melanoma 收起 <<	Phase 1 Phase 2	Suspended(Temporarily stopped ... 展开 >>for assessment. Contact ctsucontact@westat.com for specifics) 收起 <<	-	United States, California ... 展开 >> USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States, 90095 California Pacific Medical Center-Pacific Campus San Francisco, California, United States, 94115 UCSF Medical Center-Mount Zion San Francisco, California, United States, 94115 United States, Colorado University of Colorado Cancer Center - Anschutz Cancer Pavilion Aurora, Colorado, United States, 80045 United States, Michigan University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109 United States, Ohio Cleveland Clinic Foundation Cleveland, Ohio, United States, 44195 Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 United States, Oregon Clackamas Radiation Oncology Center Clackamas, Oregon, United States, 97015 Providence Milwaukie Hospital Milwaukie, Oregon, United States, 97222 Providence Newberg Medical Center Newberg, Oregon, United States, 97132 Providence Willamette Falls Medical Center Oregon City, Oregon, United States, 97045 Providence Portland Medical Center Portland, Oregon, United States, 97213 Providence Saint Vincent Medical Center Portland, Oregon, United States, 97225 Oregon Health and Science University Portland, Oregon, United States, 97239 United States, Washington PeaceHealth Southwest Medical Center Vancouver, Washington, United States, 98664 收起 <<
NCT03026517	Melanoma	Phase 1	Recruiting	January 2020	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Keith Flaherty, MD 617-724-4800 United States, New York Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Paul Chapman, MD 646-888-4162 Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Paul Chapman, MD 646-888-4162 Contact: Michael Postow, MD 646-888-4589 Principal Investigator: Paul Chapman, MD 收起 <<
NCT01777776	Locally Advanced Metastatic BR... 展开 >>AF Mutant Melanoma 收起 <<	Phase 1 Phase 2	Terminated(Study was withdrawn... 展开 >> due to scientific and business considerations.) 收起 <<	-	United States, Colorado ... 展开 >> University of Colorado Dept of Oncology Aurora, Colorado, United States, 80045 United States, Michigan Karmanos Cancer Institute Dept of Oncology Detroit, Michigan, United States, 48201 United States, New York Memorial Sloan Kettering Cancer Center Dept Oncology NY, New York, United States, 90033 United States, Oregon Oregon Health & Science University Dept. of OHSU (3) Portland, Oregon, United States, 97239 United States, Tennessee Vanderbilt University Medical Center SC - Dept of Oncology . Nashville, Tennessee, United States, 37232 Australia, New South Wales Novartis Investigative Site Westmead, New South Wales, Australia, 2145 Australia, South Australia Novartis Investigative Site Woodville, South Australia, Australia, 5011 Canada, Quebec Novartis Investigative Site Montreal, Quebec, Canada, H2X 3J4 Netherlands Novartis Investigative Site Utrecht, Netherlands, 3584CX 收起 <<
NCT01777776	-		Terminated(Study was withdrawn... 展开 >> due to scientific and business considerations.) 收起 <<	-	-
NCT01947023	BRAF V600E Mutation Present ... 展开 >> BRAF V600K Mutation Present Metastatic Thyroid Gland Carcinoma Unresectable Thyroid Gland Carcinoma 收起 <<	Phase 1	Active, not recruiting	-	United States, New York ... 展开 >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT01723202	Follicular Thyroid Cancer ... 展开 >> Insular Thyroid Cancer Papillary Thyroid Cancer Recurrent Thyroid Cancer 收起 <<	Phase 2	Active, not recruiting	December 31, 2019	United States, California ... 展开 >> University of California, San Diego San Diego, California, United States, 92093-0698 United States, Illinois University of Chicago Medical Center Chicago, Illinois, United States, 60637 United States, Massachusetts Massachusetts General Hospital, Harvard Medical School Boston, Massachusetts, United States, 02114 United States, Ohio Ohio State University Medical Center Columbus, Ohio, United States, 43210 United States, Texas The University of Texas-MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01907802	BRAF Gene Mutation ... 展开 >> Hepatic Complication Renal Failure Solid Neoplasm 收起 <<	Phase 1	Terminated	-	United States, California ... 展开 >> City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010 USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 City of Hope South Pasadena South Pasadena, California, United States, 91030 United States, Colorado University of Colorado Hospital Aurora, Colorado, United States, 80045 United States, Florida Mayo Clinic in Florida Jacksonville, Florida, United States, 32224-9980 United States, Illinois University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637 United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Michigan Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, New Jersey Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 United States, Ohio Case Western Reserve University Cleveland, Ohio, United States, 44106 Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 United States, Pennsylvania University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 United States, Wisconsin University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 Canada, Ontario University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT02231775	BRAF V600E Mutation Present ... 展开 >> BRAF V600K Mutation Present Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 收起 <<	Phase 2	Recruiting	October 31, 2019	United States, Texas ... 展开 >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Jennifer Wargo 713-745-1553 Principal Investigator: Jennifer Wargo 收起 <<
NCT01826448	V600-mutated BRAF Unresectable... 展开 >> Melanoma V600-mutated BRAF Metastatic Melanoma Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor 收起 <<	Phase 1	Terminated	-	United States, California ... 展开 >> UCLA Los Angeles, California, United States, 90024 United States, Colorado University of Colorado, Denver Aurora, Colorado, United States, 80012 United States, Tennessee Vanderbilt University Nashville, Tennessee, United States, 37232 United States, Washington Seattle Cancer Care Alliance Seattle, Washington, United States, 98109 France Institute Gustave Roussy Paris, France Germany University Hospital Essen Essen, Germany 收起 <<
NCT01713972	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Active, not recruiting	December 31, 2019	United States, Ohio ... 展开 >> Ohio State University Medical Center Columbus, Ohio, United States, 43210 United States, Texas University of Texas M.D. Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02196181	BRAF V600E Mutation Present ... 展开 >> BRAF V600K Mutation Present Stage III Cutaneous Melanoma AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 Unresectable Melanoma 收起 <<	Phase 2	Recruiting	-	-
NCT02416232	-		-	-	France ... 展开 >> GSK Investigational Site Amiens Cedex, France, 80054 GSK Investigational Site Angers, France, 49100 GSK Investigational Site Bayonne cedex, France, 64109 GSK Investigational Site Besancon cedex, France, 25030 GSK Investigational Site Bobigny, France, 93000 GSK Investigational Site Bordeaux, France, 33075 GSK Investigational Site Boulogne-Billancourt, France, 92100 GSK Investigational Site Brest cedex, France, 29609 GSK Investigational Site Caen Cedex 9, France, 14033 GSK Investigational Site Chambray-Les-Tours, France, 37170 GSK Investigational Site Clermont-Ferrand cedex 1, France, 63003 GSK Investigational Site Creteil, France, 94010 GSK Investigational Site Dijon Cedex, France, 21079 GSK Investigational Site Grenoble cedex 9, France, 38043 GSK Investigational Site La Rochelle cedex 1, France, 17019 GSK Investigational Site Le Havre, France, 76083 GSK Investigational Site Le Mans, France, 72000 GSK Investigational Site Lille, France, 59037 GSK Investigational Site Limoges cedex, France, 87042 GSK Investigational Site Lorient, France, 56322 GSK Investigational Site Lyon Cedex 08, France, 69373 GSK Investigational Site Marseille Cedex 5, France, 13385 GSK Investigational Site Montpellier cedex 5, France, 34295 GSK Investigational Site Montpellier Cedex 5, France, 34298 GSK Investigational Site Mulhouse, France, 68100 GSK Investigational Site Nantes Cedex 1, France, 44093 GSK Investigational Site Nice, France, 06202 GSK Investigational Site Nimes, France, 30029 cedex 9 GSK Investigational Site Orleans Cedex 2, France, 45067 GSK Investigational Site Paris Cedex 10, France, 75475 GSK Investigational Site Paris, France, 75006 GSK Investigational Site Pau, France, 64000 GSK Investigational Site Pierre-Benite cedex, France, 69495 GSK Investigational Site Poitiers, France, 86021 GSK Investigational Site Pringy Cedex, France, 74374 GSK Investigational Site Reims Cedex, France, 51092 GSK Investigational Site Rennes Cedex, France, 35042 GSK Investigational Site Rouen, France, 76031 GSK Investigational Site Saint-Pierre, France, 97448 GSK Investigational Site Saint-Priest en Jarez, France, 42270 GSK Investigational Site Strasbourg Cedex, France, 67091 GSK Investigational Site Thionville, France, 57126 Cedex 1 GSK Investigational Site Toulouse Cedex 9, France, 31059 GSK Investigational Site Valence Cedex 9, France, 26953 GSK Investigational Site Vandoeuvre-Les-Nancy, France, 54511 GSK Investigational Site Villejuif cedex, France, 94805 收起 <<
NCT02700763	Melanoma	Not Applicable	Recruiting	December 2019	Netherlands ... 展开 >> University Medical Center Groningen Recruiting Groningen, Netherlands, 9713 GZ Contact: Geke AP Hospers, MD, PhD +31 50 3612821 g.a.p.hospers@umcg.nl Principal Investigator: Geke A.P. Hospers, MD, PhD 收起 <<
NCT02902042	Malignant Melanoma	Phase 1 Phase 2	Recruiting	March 2022	Germany ... 展开 >> Universitätsklinikum Freiburg Active, not recruiting Freiburg, Baden-Württemberg, Germany, 79106 Klinikum Augsburg Süd Not yet recruiting Augsburg, Bavaria, Germany, 86179 Principal Investigator: Christiane Pfeiffer, PD Dr. med. Klinikum rechts der Isar Recruiting München, Bavaria, Germany, 81675 Principal Investigator: Angela Krackhardt, Prof.Dr.med. Klinikum Nürnberg Nord Recruiting Nürnberg, Bavaria, Germany, 90419 Principal Investigator: Erwin S. Schultz, Prof.Dr.med. Vivantes Klinikum im Friedrichshain Active, not recruiting Berlin Friedrichshain, Berlin, Germany, 10249 Universitätsklinikum der RWTH Aachen Not yet recruiting Aachen, Nordrhein-Westfalen, Germany, 52074 Principal Investigator: Albert Rübben, Prof.Dr.med. University Hospital Essen, Department of Dermatology, Skin Cancer Center Recruiting Essen, North Rhine-Westphalia, Germany, 45122 Contact: Dirk Schadendorf, Prof. Dr. +49 (0) 201-723 ext 4342 dirk.schadendorf@uk-essen.de Principal Investigator: Dirk Schadendorf, Prof. Dr. Sub-Investigator: Lisa Zimmer, Dr. med. Sub-Investigator: Elisabeth Livingstone, Dr. med. HELIOS Klinikum Krefeld Recruiting Krefeld, North Rhine-Westphalia, Germany, 47805 Principal Investigator: Chalid Assaf, PD Dr. med. Gesellschaft für Klinische Forschung Ludwigshafen mbH Not yet recruiting Ludwigshafen am Rhein, Rheinland-Pfalz, Germany, 67063 Principal Investigator: Edgar Dippel, Prof.Dr.med. Städtisches Klinikum Dessau Recruiting Dessau, Saxony-Anhalt, Germany, 06847 Principal Investigator: Dietrich Trebing, Dr. med. 收起 <<
NCT01543113	Melanoma	Not Applicable	Completed	-	France ... 展开 >> Centre Eugène Marquis Rennes, Bretagne, France, 35000 Rennes University Hospital Rennes, Bretagne, France, 35033 收起 <<
NCT02224781	BRAF NP_004324.2:p.V600X ... 展开 >> Metastatic Melanoma Recurrent Melanoma Stage III Cutaneous Melanoma AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 收起 <<	Phase 3	Recruiting	-	-
NCT02263898	Recurrent Melanoma ... 展开 >> Stage IV Melanoma 收起 <<	Phase 2	Withdrawn(closed without enrol... 展开 >>lment) 收起 <<	-	United States, California ... 展开 >> Jonsson Comprehensive Cancer Center Los Angeles, California, United States, 90095 收起 <<
NCT01820364	Melanoma	Phase 2	Terminated(Study was withdrawn... 展开 >> due to scientific and business considerations.) 收起 <<	-	United States, Tennessee ... 展开 >> Sarah Cannon Research Institute Onc Dept Nashville, Tennessee, United States, 37203 Australia, Victoria Novartis Investigative Site East Melbourne, Victoria, Australia, 3002 Canada, Alberta Novartis Investigative Site Edmonton, Alberta, Canada, T6G 1Z2 Germany Novartis Investigative Site Heidelberg, Germany, 69120 Spain Novartis Investigative Site Barcelona, Catalunya, Spain, 08035 Switzerland Novartis Investigative Site Zuerich, Switzerland, 8091 收起 <<
NCT02306850	Unresectable Malignant Neoplas... 展开 >>m Melanoma Metastatic Melanoma Stage IV Melanoma Stage III Melanoma 收起 <<	Phase 2	Recruiting	February 2019	United States, Missouri ... 展开 >> Saint Louis University Hospital Recruiting Saint Louis, Missouri, United States, 63101 Contact: Debra L King, RN 314-268-7061 richartstudy@gmail.com Principal Investigator: John M Richart, M.D. 收起 <<
NCT01820364	-		Terminated(Study was withdrawn... 展开 >> due to scientific and business considerations.) 收起 <<	-	-
NCT01582997	Cancer	Phase 1	Completed	-	Japan ... 展开 >> GSK Investigational Site Shizuoka, Japan, 411-8777 GSK Investigational Site Tokyo, Japan, 104-0045 收起 <<
NCT01754376	Melanoma	Phase 2	Terminated(changes in availabl... 展开 >>e treatments for melanoma) 收起 <<	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02113 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 收起 <<
NCT01754376	-		Terminated(changes in availabl... 展开 >>e treatments for melanoma) 收起 <<	-	-
NCT01400451	Melanoma	Phase 1	Terminated(More than 2 of 6 pa... 展开 >>tients treated experienced dose limiting toxicities.) 收起 <<	-	United States, California ... 展开 >> University Of California Los Angeles Los Angeles, California, United States, 90095 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 Dana Farber Cancer Inst Boston, Massachusetts, United States, 02215 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT01701037	Recurrent Melanoma ... 展开 >> Stage IIB Melanoma (Locally Advanced) Stage IIC Melanoma (Locally Advanced) Stage IIIA Melanoma Stage IIIB Melanoma Stage IIIC Melanoma Stage IV Melanoma (Limited, Resectable) 收起 <<	Phase 2	Terminated(PI leaving VICC, lo... 展开 >>w future accrual predicted, continued funding improbable,) 收起 <<	-	United States, Tennessee ... 展开 >> Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232-6838 收起 <<
NCT01701037	-		Terminated(PI leaving VICC, lo... 展开 >>w future accrual predicted, continued funding improbable,) 收起 <<	-	-
NCT00338377	Melanoma	Phase 2	Recruiting	February 2019	United States, Texas ... 展开 >> The University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Patrick Hwu, MD 713-792-2921 phwu@mdanderson.org Principal Investigator: Patrick Hwu, MD 收起 <<
NCT01400451	-		Terminated(More than 2 of 6 pa... 展开 >>tients treated experienced dose limiting toxicities.) 收起 <<	-	-
NCT01721603	BRAFV600E Melanoma Patients	Phase 2	Terminated(Low accrual)	-	United States, California ... 展开 >> University of San Francisco, California San Francisco, California, United States, 94115 收起 <<
NCT02452294	Malignant Melanoma ... 展开 >> Metastases 收起 <<	Phase 2	Recruiting	July 2018	Germany ... 展开 >> Department of Dermatology, University Hopsital Recruiting Dresden, Germany, 01307 Contact: Friedegund Meier, MD ++49 351 458 ext 3677 Friedegund.Meier@uniklinikum-dresden.de Department of Dermatology, University Hospital Recruiting Tuebingen, Germany, 72076 Contact: Claus Garbe, MD ++49 7071 29 ext 87110 claus.garbe@med.uni-tuebingen.de Contact: Thomas Eigentler, MD ++49 7071 29 ext 85748 thomas.eigentler@med.uni-tuebingen.de 收起 <<
NCT01721603	-		Terminated(Low accrual)	-	-
NCT02143050	Melanoma	Phase 1 Phase 2	Recruiting	June 2020	United States, Kentucky ... 展开 >> James Graham Brown Cancer Center-Universityof Louisville Recruiting Louisville, Kentucky, United States, 40202 Contact: Jason A Chesney, MD, PhD 502-562-3429 jason.chesney@louisville.edu Contact: Christina LaDuke 502-217-5205 christy.laduke@louisville.edu Sub-Investigator: Donald M Miller, MD, PhD Sub-Investigator: Kelly M McMasters, MD, PhD Sub-Investigator: Sucheta Telang, MD James Graham Brown Cancer Center Recruiting Louisville, Kentucky, United States, 40202 Contact: Karen Carter, BSN 502-562-3690 kmcart05@louisville.edu Contact: Christina LaDuke, BS 502-217-5205 christi.laduke@louisville.edu 收起 <<
NCT01700699	-		Unknown	October 2013	Italy ... 展开 >> Department of Medicine and Surgery, Univeristy of Salerno Recruiting Baronissi, Salerno, Italy, 84081 Contact: Mario Vitale, MD +39 089672539 mavitale@unisa.it Principal Investigator: Mario Vitale, MD 收起 <<
NCT01495988	-		Terminated(Slow accrual; toxic... 展开 >>ity; change in priorities) 收起 <<	-	-
NCT02052193	Metastatic Melanoma (Carrying ... 展开 >>BRAF V600 Mutation) 收起 <<	Phase 2	Terminated(Second cohort not o... 展开 >>pened because Simon-Two_Step model failed) 收起 <<	December 2017	Germany ... 展开 >> Department of Dermatology Tuebingen, BW, Germany, 72076 收起 <<
NCT01495988	Melanoma Meta... 展开 >>static Melanoma 收起 <<	Phase 2	Terminated(Slow accrual; toxic... 展开 >>ity; change in priorities) 收起 <<	-	United States, California ... 展开 >> The Angeles Clinic Los Angeles, California, United States, 90025 United States, Colorado University of Colorado Cancer Center Aurora, Colorado, United States, 80045 United States, District of Columbia Georgetown Lombardi Comprehensive Cancer Center Washington, D.C., District of Columbia, United States, 20007 Washington Cancer Institute at MedStar Washington Hospital Center Washington, D.C., District of Columbia, United States, 20010 United States, Maryland Harry and Jeannette Weinberg Cancer Institute at Franklin Square Baltimore, Maryland, United States, 21237 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Beth Israel Deaconess Medical Center (BIDMC) Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, New York NYU Clinical Cancer Center New York, New York, United States, 10016 Columbia University Medical Center New York, New York, United States, 10032 United States, Ohio OSU Comprehensive Cancer Center Columbus, Ohio, United States, 43210 United States, Pennsylvania University of Pittsburgh Medical Center Pittsburgh, Pennsylvania, United States, 15232 United States, Tennessee Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232 United States, Washington University of Washington Medical Center Seattle, Washington, United States, 98109 收起 <<
NCT02427893	Melanoma	Phase 3	Withdrawn(no patients were enr... 展开 >>olled) 收起 <<	-	United States, Maryland ... 展开 >> The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States, 21231 收起 <<
NCT01719380	Colorectal Cancer	Phase 1 Phase 2	Active, not recruiting	July 31, 2019	-
NCT01340846	Cancer	Phase 1	Completed	-	United States, Arizona ... 展开 >> GSK Investigational Site Scottsdale, Arizona, United States, 85259 United States, Florida GSK Investigational Site Sarasota, Florida, United States, 34232 United States, Michigan GSK Investigational Site Detroit, Michigan, United States, 48201 United States, Ohio GSK Investigational Site Columbus, Ohio, United States, 43210 United States, Oklahoma GSK Investigational Site Oklahoma City, Oklahoma, United States, 73104 United States, South Carolina GSK Investigational Site Greenville, South Carolina, United States, 29605 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37203 United States, Utah GSK Investigational Site Salt Lake City, Utah, United States, 84112 Australia, Western Australia GSK Investigational Site Nedlands, Western Australia, Australia, 6009 United Kingdom GSK Investigational Site Headington, United Kingdom, OX3 7LJ GSK Investigational Site London, United Kingdom, W1G 6AD 收起 <<
NCT01340833	Cancer	Phase 1	Completed	-	United States, Washington ... 展开 >> GSK Investigational Site Tacoma, Washington, United States, 98418 收起 <<
NCT01758575	-		Terminated	-	Netherlands ... 展开 >> VU University Medical Center Amsterdam, Netherlands, 1081HV 收起 <<
NCT02354690	Metastatic Melanoma	Phase 1 Phase 2	Active, not recruiting	August 2020	Denmark ... 展开 >> Center for Cancer Immune Therapy, Dept. of Haematology/Oncology Copenhagen, Herlev, Denmark, 2730 收起 <<
NCT02967692	Melanoma	Phase 3	Recruiting	February 13, 2020	-
NCT02649972	Histiocytic Disorders	Phase 2	Recruiting	January 2019	United States, New York ... 展开 >> Memoral Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Eli Diamond, MD 212-639-7576 Contact: David Hyman, MD 646-888-4544 Principal Investigator: Eli Diamond, MD 收起 <<
NCT01143753	Neoplasms	Phase 1	Completed	-	Australia, South Australia ... 展开 >> Royal Adelaide Hospital; Oncology Adelaide, South Australia, Australia, 5000 Australia, Victoria Austin Hospital; Medical Oncology Heidelberg, Victoria, Australia, 3084 Royal Melbourne Hospital; Hematology and Medical Oncology Parkville, Victoria, Australia, 3052 Denmark Rigshospitalet, Onkologisk Klinik København Ø, Denmark, 2100 Spain Hospital Univ Vall d'Hebron; Servicio de Oncologia Barcelona, Spain, 08035 收起 <<
NCT02281760	BRAF V600E Mutation	Phase 2	Completed	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT01596140	Advanced Cancer ... 展开 >> Solid Tumor 收起 <<	Phase 1	Active, not recruiting	December 2020	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02836548	Melanoma Skin... 展开 >> Neoplasms 收起 <<	Phase 1 Phase 2	Recruiting	October 2019	Netherlands ... 展开 >> Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital Recruiting Amsterdam, Netherlands, 1066 CX Contact: N Steeghs, MD, PhD 收起 <<
NCT01519427	Recurrent Melanoma ... 展开 >> Stage IIIA Melanoma Stage IIIB Melanoma Stage IIIC Melanoma Stage IV Melanoma 收起 <<	Phase 2	Terminated(Study terminated du... 展开 >>e to slow accrual) 收起 <<	-	United States, Georgia ... 展开 >> Emory University Atlanta, Georgia, United States, 30322 United States, New Jersey Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 United States, Tennessee Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232 United States, Virginia Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States, 23298 收起 <<
NCT02382549	Melanoma	Phase 1 Phase 2	Recruiting	June 2020	United States, Virginia ... 展开 >> Cancer Center at the University of Virginia Recruiting Charlottesville, Virginia, United States, 22908 收起 <<
NCT02610361	Solid Tumors	Phase 1	Completed	-	Australia, New South Wales ... 展开 >> Chris O'Brien Lifehouse Camperdown, New South Wales, Australia, 2050 North Coast Cancer Institute Port Macquarie, New South Wales, Australia, 2444 Prince of Wales Hospital Randwick, New South Wales, Australia, 2031 Westmead Hospital Westmead, New South Wales, Australia, 2145 Australia, Queensland Tasman Oncology Research Ltd Southport, Queensland, Australia, 4215 Princess Alexandra Hospital Woolloongabba, Queensland, Australia, 4102 Australia, South Australia Royal Adelaide Hospital Adelaide, South Australia, Australia, 5000 The Queen Elizabeth Hospital Woodville South, South Australia, Australia, 5011 Australia, Victoria Box Hill Hospital Box Hill, Victoria, Australia, 3128 Monash Medical Centre Clayton, Victoria, Australia, 3168 Austin Health Heidelberg, Victoria, Australia Cabrini Hospital Malvern, Victoria, Australia, 3144 The Alfred Hospital Melbourne, Victoria, Australia, 3004 Peter MacCallum Cancer Centre Melbourne, Victoria, Australia Royal Melbourne Hospital Parkville, Victoria, Australia Australia, Western Australia Linear Clinical Research Limited Nedlands, Western Australia, Australia, 6009 New Zealand Christchurch Hospital Christchurch, New Zealand, 8011 Dunedin Public Hospital Dunedin, New Zealand, 9106 Waikato Hospital Hamilton, New Zealand Wellington Hospital Wellington, New Zealand 收起 <<
NCT01286753	Neoplasms	Phase 2	Completed	-	United States, California ... 展开 >> Torrance, California, United States, 90502 United States, Connecticut New Haven, Connecticut, United States, 06510 United States, Illinois Chicago, Illinois, United States, 60637 United States, Maryland Baltimore, Maryland, United States, 21231 United States, Massachusetts Boston, Massachusetts, United States, 02114 Boston, Massachusetts, United States, 02215 United States, New York New York, New York, United States, 10017 United States, Pennsylvania Philadelphia, Pennsylvania, United States, 19104 United States, Texas Houston, Texas, United States, 77030 France Lyon, France, 69008 Paris, France, 75651 Villejuif, France, 94805 Italy Milano, Lombardia, Italy, 20133 Pisa, Toscana, Italy, 56124 Netherlands Groningen, Netherlands, 9700 RB Leiden, Netherlands, 2300 RC 收起 <<
NCT01286753	-		Completed	-	-
NCT02310451	Metastatic Melanoma	Not Applicable	Unknown	December 2016	France ... 展开 >> CHU de Nice ^Hôpital de l'Archet Recruiting Nice, France, 06200 Contact: Vanina OLIVERI, CRA 0033 4 92 03 42 54 oliveri.v@chu-nice.fr 收起 <<
NCT01519427	-		Terminated(Study terminated du... 展开 >>e to slow accrual) 收起 <<	-	-
NCT01531361	Advanced Malignant Neoplasm ... 展开 >> BRAF Gene Mutation Metastatic Malignant Neoplasm Recurrent Malignant Neoplasm Refractory Malignant Neoplasm 收起 <<	Phase 1	Active, not recruiting	February 28, 2020	United States, Texas ... 展开 >> M D Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02456701	Thyroid Cancer	Phase 1	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT01336634	Cancer	Phase 2	Active, not recruiting	December 1, 2020	-
NCT01336634	-		Active, not recruiting	-	-
NCT02410863	Malignant Melanoma	Phase 2	Terminated(lack of recruitment... 展开 >> due to changed therapy options) 收起 <<	-	Germany ... 展开 >> National Centre for Tumour Diseases (NCT) Heidelberg, BW, Germany, 69120 University Hospital Tübingen Tübingen, BW, Germany, 72076 Elbe Kliniken Stade - Buxtehude GmbH, Clinic for Dermatology Buxtehude, Lower Saxony, Germany, 21614 University Hospital Essen Essen, NRW, Germany, 45147 University Hospital Mainz, Clinic for Dermatology Mainz, Rhineland-Palatinate, Germany, 55131 Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden Dresden, Saxony, Germany, 01307 收起 <<
NCT01835184	Recurrent Melanoma ... 展开 >> Stage IIIA Melanoma Stage IIIB Melanoma Stage IIIC Melanoma Stage IV Melanoma Unspecified Adult Solid Tumor, Protocol Specific 收起 <<	Phase 1	Terminated	-	United States, Georgia ... 展开 >> Emory University/Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Virginia Virginia Commonwealth University Richmond, Virginia, United States, 23298 收起 <<
NCT01616199	Advanced BRAF-mutant Cancers	Phase 1 Phase 2	Terminated(slow accrual)	-	United States, Florida ... 展开 >> H. Lee Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, New York New York University New York, New York, United States, 10016 United States, Pennsylvania University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States, 15232 United States, Tennessee Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232 收起 <<
NCT01584648	-		Active, not recruiting	-	-
NCT01584648	Melanoma	Phase 3	Active, not recruiting	October 15, 2018	-
NCT01750918	Cancer	Phase 2	Active, not recruiting	April 30, 2019	United States, Arizona ... 展开 >> Novartis Investigative Site Scottsdale, Arizona, United States, 85259 United States, California Novartis Investigative Site San Francisco, California, United States, 94115 United States, Massachusetts Novartis Investigative Site Boston, Massachusetts, United States, 02114 Novartis Investigative Site Boston, Massachusetts, United States, 02215 United States, New York Novartis Investigative Site New York, New York, United States, 10065 United States, North Carolina Novartis Investigative Site Chapel Hill, North Carolina, United States, 27599 United States, Pennsylvania Novartis Investigative Site Philadelphia, Pennsylvania, United States, 19104 United States, Tennessee Novartis Investigative Site Nashville, Tennessee, United States, 37203 Belgium Novartis Investigative Site Bruxelles, Belgium, 1200 Novartis Investigative Site Leuven, Belgium, 3000 France Novartis Investigative Site Paris cedex 12, France, 75571 Novartis Investigative Site Villejuif Cedex, France, 94805 Italy Novartis Investigative Site Milano, Lombardia, Italy, 20162 Novartis Investigative Site Candiolo (TO), Piemonte, Italy, 10060 Japan Novartis Investigative Site Aichi, Japan, 464-8681 Novartis Investigative Site Chiba, Japan, 277-8577 Netherlands Novartis Investigative Site Amsterdam, Netherlands, 1066 CX Novartis Investigative Site Utrecht, Netherlands, 3584 CX Spain Novartis Investigative Site Barcelona, Spain, 08035 United Kingdom Novartis Investigative Site Birmingham, United Kingdom, B15 2TH 收起 <<
NCT01767454	Solid Tumours	Phase 1	Completed	-	United States, California ... 展开 >> GSK Investigational Site Los Angeles, California, United States, 90025 GSK Investigational Site San Francisco, California, United States, 94115 United States, Massachusetts GSK Investigational Site Boston, Massachusetts, United States, 02215 United States, Missouri GSK Investigational Site Saint Louis, Missouri, United States, 63110 United States, New York GSK Investigational Site New York, New York, United States, 10065 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37232 United States, Texas GSK Investigational Site Houston, Texas, United States, 77030 收起 <<
NCT01072175	Cancer	Phase 2	Completed	-	United States, California ... 展开 >> Novartis Investigative Site Los Angeles, California, United States, 90025 Novartis Investigative Site San Francisco, California, United States, 94115 United States, Colorado Novartis Investigative Site Aurora, Colorado, United States, 80045 United States, Connecticut Novartis Investigative Site New Haven, Connecticut, United States, 06520 United States, Florida Novartis Investigative Site Tampa, Florida, United States, 33612 United States, Maryland Novartis Investigative Site Lutherville-Timonium, Maryland, United States, 21093 United States, Massachusetts Novartis Investigative Site Boston, Massachusetts, United States, 02114 Novartis Investigative Site Boston, Massachusetts, United States, 02215 United States, Minnesota Novartis Investigative Site Rochester, Minnesota, United States, 55905 United States, Pennsylvania Novartis Investigative Site Philadelphia, Pennsylvania, United States, 19104 United States, Tennessee Novartis Investigative Site Nashville, Tennessee, United States, 37203 Novartis Investigative Site Nashville, Tennessee, United States, 37232 United States, Texas Novartis Investigative Site Houston, Texas, United States, 77030-4009 Australia, New South Wales Novartis Investigative Site Westmead, New South Wales, Australia, 2145 Australia, Victoria Novartis Investigative Site Heidelberg, Victoria, Australia, 3084 收起 <<
NCT01878396	-		Unknown	December 2017	Italy ... 展开 >> Vanna Chiarion-Sileni, MD Recruiting Padova, PD, Italy, 35128 Contact: Vanna Chiarion-Sileni, MD 0039 0498215931 mgaliz@tiscali.it 收起 <<
NCT01943422	Melanoma	Phase 1	Completed	-	United States, Pennsylvania ... 展开 >> Hillman Cancer Center Pittsburgh, Pennsylvania, United States, 15232 收起 <<
NCT00880321	Cancer	Phase 1	Completed	-	United States, California ... 展开 >> GSK Investigational Site Los Angeles, California, United States, 90025 United States, New York GSK Investigational Site New York, New York, United States, 10016 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37203 United States, Texas GSK Investigational Site Houston, Texas, United States, 77030 Australia, New South Wales GSK Investigational Site Randwick, New South Wales, Australia, 2031 GSK Investigational Site Westmead, New South Wales, Australia, 2145 Australia, South Australia GSK Investigational Site Adelaide, South Australia, Australia, 5000 Australia, Western Australia GSK Investigational Site Nedlands, Western Australia, Australia, 6009 收起 <<
NCT02143999	-		Completed	-	Italy ... 展开 >> Policlinico Ospedaliero Ss Annunziata; U.O. Di Clinica Oncologica Chieti, Abruzzo, Italy, 66100 IRCCS IST. Tumori Fondaz. Pascale; S.C. Oncologia Medica,Melanoma,Immunoterapia E Terapie Innovative Napoli, Campania, Italy, 80131 Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica Bologna, Emilia-Romagna, Italy, 40138 Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST);U.O. di Immunoterapia Meldola, Emilia-Romagna, Italy, 47014 Arcispedale Santa Maria Nuova; Oncologia Reggio Emilia, Emilia-Romagna, Italy, 42100 Policlinico Universitario Campus Biomedico; Uoc Oncologia Medica Roma, Lazio, Italy, 00128 Policlinico Umberto i di Roma; dip. Scienze Radiologiche, Oncologiche, Anatomopatologiche Roma, Lazio, Italy, 00161 IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A Genova, Liguria, Italy, 16132 Asst Papa Giovanni XXIII; Oncologia Medica Bergamo, Lombardia, Italy, 24128 Az. Osp. Spedali Civili; Divisione Di Oncologia - Iii Medicina Brescia, Lombardia, Italy, 25123 Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2 Milano, Lombardia, Italy, 20133 Irccs Istituto Europeo Di Oncologia (Ieo); Unita' Di Ricerca Traslazionale Del Melanoma Milano, Lombardia, Italy, 20141 Fondazione Del Piemonte Per L'oncologia IRCC Di Candiolo Candiolo, Piemonte, Italy, 10060 Azienda Sanitaria Ospedaliera s. Croce e Carle; Oncologia Medica Cuneo, Piemonte, Italy, 12100 Ospedale Maggiore Della Carita; Oncologia Medica Novara, Piemonte, Italy, 28100 Azienda Ospedaliera Città della Salute e della Scienza di Torino Torino, Piemonte, Italy, 10126 Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari Bari, Puglia, Italy, 70124 Policlinico P. Giaccone; Istituto Di Oncologia, Clinica Medica 1 Palermo, Sicilia, Italy, 90127 Ospedale S. Vincenzo; Oncologia Medica Taormina, Sicilia, Italy, 98030 Azienda Sanitaria di Firenze Presidio Palagi - SC Dermatologia II e Fisioterapia Dermatologica Firenze, Toscana, Italy, 50125 Azlenda Ospendaliero-Universitaria Pisana; C.O. Oncologia 2 Pisa, Toscana, Italy, 56100 Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica Siena, Toscana, Italy, 53100 Azienda Ospedaliero Universitaria di Ferrara - U.O. Di Oncologia Cona (FE), Veneto, Italy, 44124 Azienda Ospedaliera di Verona-Policlinico G.B. Rossi; Oncologia Medica Verona, Veneto, Italy, 37134 收起 <<
NCT01597908	Melanoma	Phase 3	Active, not recruiting	March 18, 2019	-
NCT02314143	Melanoma	Phase 2	Completed	-	France ... 展开 >> GSK Investigational Site Bordeaux, France, 33075 GSK Investigational Site Marseille cedex 5, France, 13385 GSK Investigational Site Reims Cedex, France, 51092 GSK Investigational Site Rennes Cedex, France, 35042 GSK Investigational Site Villejuif cedex, France, 94805 Spain GSK Investigational Site Barcelona, Spain, 08036 GSK Investigational Site Madrid, Spain, 28041 收起 <<
NCT01603212	Melanoma	Phase 1 Phase 2	Completed	-	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01894672	Melanoma	Phase 2	Completed	-	United States, New Jersey ... 展开 >> Memorial Sloan Kettering Cancer Center at Basking Ridge Basking Ridge, New Jersey, United States United States, New York Memorial Sloan Kettering Cancer Center at Commack Commack, New York, United States, 11725 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Memorial Sloan Kettering Cancer Center at Mercy Medical Center Rockville Centre, New York, United States, 11570 Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center Sleepy Hollow, New York, United States, 10591 收起 <<
NCT01711632	Hairy Cell Leukemia	Phase 2	Active, not recruiting	October 2019	United States, California ... 展开 >> Scripps Clinic La Jolla, California, United States, 92037 United States, Illinois Northwestern University Evanston, Illinois, United States, 60208 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, Ohio Ohio State University Columbus, Ohio, United States, 43210 收起 <<
NCT01597908	-		Active, not recruiting	-	-
NCT01894672	-		Completed	-	-
NCT02145143	Thyroid Carcinoma	Not Applicable	Active, not recruiting	May 2019	United States, New York ... 展开 >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT02038348	Metastatic Melanoma	Phase 2	Unknown	June 2016	France ... 展开 >> Assistance Publique Hopitaux de Marseille Recruiting Marseille, France, 13354 Contact: caroline gaudy caroline.gaudy@ap-hm.fr Principal Investigator: caroline gaudy 收起 <<
NCT01619774	Melanoma	Phase 2	Completed	-	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01072175	-		Completed	-	-
NCT03410875	Hairy Cell Leukemia ... 展开 >> Leukemia Leukemia, Hairy Cell 收起 <<	Phase 2	Recruiting	January 2020	United States, Connecticut ... 展开 >> Yale University Not yet recruiting New Haven, Connecticut, United States, 06511 Contact: Gottfried von Keudell, MD/PhD 203-737-5312 United States, Massachusetts Dana Farber Cancer Institute Not yet recruiting Boston, Massachusetts, United States, 02115 Contact: Eric Winer, MD 617-632-6876 United States, New York Memorial Sloan - Kettering Cancer Center Recruiting New York, New York, United States, 10021 Contact: Jae Park, MD 212-639-4048 parkj6@mskcc.org 收起 <<
NCT01619774	-		Completed	-	-
NCT02089724	-		Recruiting	April 2019	United States, New York ... 展开 >> Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Eli L. Diamond, MD, PhD diamonel@mskcc.org Principal Investigator: Eli L. Diamond, MD, PhD Sub-Investigator: Omar Abdel-Wahab, MD France AP-HP, Groupe Hospitalier Pitié-Salpêtrière Recruiting Paris, France, 75013 Contact: Julien Haroche, MD, PhD +33 1 42 17 80 37 julien.haroche@psl.aphp.fr Contact: Fleur Cohen Aubart, MD, PhD +33 1 42 17 82 42 fleur.cohen@psl.aphp.fr Principal Investigator: Julien Haroche, MD, PhD Sub-Investigator: Fleur Cohen Aubart, MD, PhD Sub-Investigator: Zahir Amoura, MD, MSc 收起 <<
NCT02296996	Malignant Melanoma	Phase 2	Active, not recruiting	December 2017	Belgium ... 展开 >> UZ Brussel Brussels, Belgium, 1090 收起 <<
NCT01037127	Cancer	Phase 2	Completed	-	United States, California ... 展开 >> GSK Investigational Site Los Angeles, California, United States, 90024 United States, Colorado GSK Investigational Site Aurora, Colorado, United States, 80045 United States, New York GSK Investigational Site New York, New York, United States, 10016 United States, Pennsylvania GSK Investigational Site Philadelphia, Pennsylvania, United States, 19104 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37203 GSK Investigational Site Nashville, Tennessee, United States, 37232-6307 United States, Texas GSK Investigational Site Houston, Texas, United States, 77030-4009 Australia, New South Wales GSK Investigational Site Westmead, New South Wales, Australia, 2145 Australia, Victoria GSK Investigational Site East Melbourne, Victoria, Australia, 3002 Australia, Western Australia GSK Investigational Site Nedlands, Western Australia, Australia, 6009 收起 <<
NCT01841463	Advanced or Inoperable Maligna... 展开 >>nt Melanoma With BRAF Mutation 收起 <<	Phase 1	Suspended(Sponsor decision not... 展开 >> related to patient safety) 收起 <<	March 2016	United States, California ... 展开 >> UCSF Medical Center at Mount Zion South San Francisco, California, United States, 94115 United States, Colorado University of Colorado Anschutz Medical Campus Aurora, Colorado, United States, 80045 United States, District of Columbia Georgetown-Lombardi Comprehensive Cancer Ctr Washington, District of Columbia, United States, 20057 United States, Texas The University of Texas, MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01726738	Stage III Melanoma ... 展开 >> Stage IV Melanoma Unresectable Melanoma BRAF Mutant Melanoma 收起 <<	Phase 2	Completed	-	United States, North Carolina ... 展开 >> Lineberger Comprehensive Cancer Center, University of North Carolina Chapel Hill, North Carolina, United States, 27599 收起 <<
NCT01037127	-		Completed	-	-

CAS号	1315330-11-0
分子式	C₂₉H₃₁F₃N₆O₂
分子量	552.591

TAK1/MAP4K2 inhibitor 1 {[allProObj[0].p_purity_real_show]}

TAK1/MAP4K2 inhibitor 1 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

TAK1/MAP4K2 inhibitor 1 质控信息

TAK1/MAP4K2 inhibitor 1 生物活性

TAK1/MAP4K2 inhibitor 1 临床研究

TAK1/MAP4K2 inhibitor 1 参考文献

TAK1/MAP4K2 inhibitor 1 实验方案

TAK1/MAP4K2 inhibitor 1 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

别名
运输	蓝冰

TAK1/MAP4K2 inhibitor 1 {[allProObj[0].p_purity_real_show]}

TAK1/MAP4K2 inhibitor 1 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

TAK1/MAP4K2 inhibitor 1 质控信息

TAK1/MAP4K2 inhibitor 1 生物活性

TAK1/MAP4K2 inhibitor 1 临床研究

TAK1/MAP4K2 inhibitor 1 参考文献

TAK1/MAP4K2 inhibitor 1 实验方案

TAK1/MAP4K2 inhibitor 1 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

TAK1/MAP4K2 inhibitor 1 纯度/质量文件产品仅供科研